Related Experiment Video
Updated: Dec 10, 2025

Preclinical Assessment of the Bioactivity of the Anticancer Coumarin OT48 by Spheroids, Colony Formation Assays, and Zebrafish Xenografts
Published on: June 26, 2018
Statins as Anticancer Agents in the Era of Precision Medicine
Joseph Longo1,2, Jenna E van Leeuwen1,2, Mohamad Elbaz1
1Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
Abstract:
Statins are widely prescribed cholesterol-lowering drugs that inhibit HMG-CoA reductase (HMGCR), the rate-limiting enzyme of the mevalonate metabolic pathway. Multiple lines of evidence indicate that certain cancers depend on the mevalonate pathway for growth and survival, and, therefore, are vulnerable to statin therapy. However, these immediately available, well-tolerated, and inexpensive drugs have yet to be successfully repurposed and integrated into cancer patient care. In this review, we highlight recent advances and outline important considerations for advancing statins to clinical trials in oncology.
Insights
Statins, cholesterol drugs targeting the mevalonate pathway, show promise for cancer treatment. Further research is needed to integrate these drugs into oncology care.
Area of Science:
- Oncology
- Biochemistry
- Pharmacology
Background:
- Statins are widely used cholesterol-lowering medications.
- They inhibit HMG-CoA reductase (HMGCR), a key enzyme in the mevalonate pathway.
- Cancer cells often rely on the mevalonate pathway for growth and survival.
Purpose of the Study:
- To review recent advances in statin repurposing for cancer treatment.
- To outline considerations for advancing statins into oncology clinical trials.
Main Methods:
- Literature review of existing research on statins and cancer.
- Analysis of the mevalonate pathway's role in cancer progression.
- Discussion of challenges and opportunities for clinical translation.
Main Results:
- Evidence suggests certain cancers are vulnerable to statin therapy.
- Statins are well-tolerated, inexpensive, and readily available drugs.
- Repurposing statins for oncology faces hurdles in clinical integration.
Conclusions:
- Statins represent a promising, accessible therapeutic option for specific cancers.
- Further investigation and strategic planning are crucial for clinical implementation.
- Advancing statins into oncology trials requires addressing current challenges.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Cancer
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer Prevention
Some...

